Muslimah Amila Hanifan, Tiara Marita Restie, Djauhari Hofiya, Dewantara Muhammad Hafizh, Susandi Evan, Indrati Agnes Rengga, Alisjahbana Bachti, Soeroto Arto Yuwono, Wisaksana Rudi
Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Research Center for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung 40161, Indonesia.
Vaccines (Basel). 2023 Jul 30;11(8):1300. doi: 10.3390/vaccines11081300.
In August 2022, Indonesia prioritized healthcare workers to receive the second booster dose. We conducted a sequential serosurvey to understand the dynamics of the antibody titers. The first serosurvey, which was conducted in June 2021, 1-6 months after Sinovac vaccination, showed a median antibody level of 41.4 BAU/mL (interquartile range (IQR): 10-629.4 BAU/mL). The second serosurvey was conducted one month (August 2021) after the first Moderna booster vaccine and showed a median level of 4000 BAU/mL (IQR: 3081-4000 BAU/mL). The last serosurvey was conducted a year (August 2022) after the booster and showed a median level of 4000 BAU/mL (IQR: 4000-4000 BAU/mL). In this last survey, only 39 (11.9%) of healthcare workers had antibody levels below the maximum level of 4000 BAU/mL. Thus, one year after the first booster dose, we did not observe the waning of antibody levels. The average increase was perhaps because of natural infection. Based on these considerations, we believe that a second booster dose was not necessary for this category of subjects at that time. Because vaccine supply is often limited, priority could be given to the general population or other high-risk patient groups with low antibody titers based on serological tests.
2022年8月，印度尼西亚将医护人员列为优先接种第二剂加强针的人群。我们开展了一项序贯血清学调查，以了解抗体滴度的变化动态。第一次血清学调查于2021年6月进行，即在接种科兴疫苗1至6个月后，结果显示抗体水平中位数为41.4 BAU/mL（四分位间距（IQR）：10 - 629.4 BAU/mL）。第二次血清学调查在接种第一剂莫德纳加强针疫苗一个月后（2021年8月）进行，结果显示抗体水平中位数为4000 BAU/mL（IQR：3081 - 4000 BAU/mL）。最后一次血清学调查在加强针接种一年后（2022年8月）进行，结果显示抗体水平中位数为4000 BAU/mL（IQR：4000 - 4000 BAU/mL）。在最后这次调查中，只有39名（11.9%）医护人员的抗体水平低于4000 BAU/mL的最高水平。因此，在首次接种加强针一年后，我们并未观察到抗体水平下降。抗体水平平均升高可能是由于自然感染。基于这些考虑，我们认为当时这类人群没有必要接种第二剂加强针。由于疫苗供应往往有限，可根据血清学检测结果，将优先权给予普通人群或其他抗体滴度较低的高风险患者群体。
